<unk>  is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) that is FDA approved for the treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype (add-on maintenance treatment). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include oropharyngeal pain (2%).
Reslizumab
Tocilizumab
Risankizumab
Natalizumab
Ravulizumab
Tildrakizumab
Mogamulizumab
Ixekizumab